Retrospective Evaluation of Commercial Spacers in Prostate Cancer Patients

Evaluation of Commercially Available Implantable Spacers, in Prostate Cancer Patients Undergoing Radiotherapy

Assessment of efficacy and safety of implantable spacers when used to reduce the radiation dose delivered to the organs at risk in prostate cancer patients undergoing radiotherapy.

Multi-center, retrospective, observational study for assessment of rectal dose reduction following implantation of the BioProtect Balloon Implant System

Inclusion Criteria:

- Males at least 18 years of age, who have undergone radiation therapy with implantable spacers

Exclusion Criteria:

• Patients whose clinical and pathological data are not available.
• Patients have been histologically diagnosed with invasive adenocarcinoma that is extracapsular with posterior extension